SOTIO Biotech AG
SOTIO, an international biotechnology company, is developing new therapies focusing on the treatment of cancer and autoimmune diseases. SOTIO pursues this through its in-house research and clinical development and related services, collaborations with external partners, in-licensing deals, investments and acquisitions. SOTIO has established the key capabilities required for research, preclinical and clinical development, commercial planning and market access, with the goal to rapidly advance programs in its portfolio through clinical development towards commercialization. The most advanced project is an active cellular immunotherapy (ACI) on the basis of dendritic cells; the safety and efficacy of it being tested in multiple Phase I to Phase III clinical trials in oncology indications.